基于PCA-MQIF、DBNs建模结合多目标GA集成优化缓控释药系统组分配比和工艺优化的效果研究
结题报告
批准号:
81973155
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
仇丽霞
依托单位:
学科分类:
流行病学方法与卫生统计
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
仇丽霞
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
创新药物研发是国家战略,缓控释药恒速释放、血药浓度平稳。但组分配比、工艺优化尚存在问题:未考虑组分总和为1,试验设计方案不合理;Scheffe多项式未考虑组分不独立和累积释放度重复测量特征;将多目标转化为单目标优化,不能给出Pareto非劣解;成为制约缓控释药物发展的瓶颈。本课题将编写图文并茂、便于研究者使用的混料配比与工艺优化设计方案;通过logratio或球坐标变换消除混料约束,针对重复测量特征,建立消除共线性的主成分改进二次推断函数,或者构建整体效应的动态贝叶斯网络模型;采用多目标遗传算法集成优化,实现缓控释药物混料组分精确配比和工艺条件精准选择;在SGALAB1003beat5基础上构建智能整合解离器,标准测试函数测试程序可靠性,创建多目标遗传算法集成优化工具箱;利用缓控释文献数据评价算法优良性;通过创新药物的实验回代,验证建模和优化策略效果;为缓控释“精准”制药奠定方法学基础。
英文摘要
Innovative drug research and development is a national strategy, with sustained release of controlled release drugs and stable blood drug concentrations. However, there are still problems in group distribution ratio and process optimization: The sum of the components is not considered to be 1, and the experimental design scheme is unreasonable; the Scheffe polynomial does not consider the repeated measurement characteristics of component independence and cumulative release; Transforming multi-objective into single-objective optimization can not give Pareto's non-inferior solution, which is the bottleneck restricting the development of sustained and controlled release drugs. This topic will compile the optimum design scheme of mix proportion and process, which is full of pictures and texts and is easy for researchers to use. Mixture constraints are eliminated by log ratio or spherical coordinate transformation, and a quadratic inference function for eliminating collinearity of principal components is established, or a dynamic Bayesian network model for global effects is constructed. Integrative optimization of multi-objective genetic algorithm was used to achieve accurate mixing ratio and process conditions of slow-release and controlled-release drug mixtures. On the basis of SGALAB1003beat5, an intelligent integrated dissociator is constructed, the reliability of the standard test function is tested, and a multi-objective genetic algorithm integrated optimization toolbox is created.Evaluate the performance of the algorithm by using controlled-release literature data; validate the effectiveness of the modeling and optimization strategy through experimental retrospect of innovative drugs. To lay a methodological foundation for sustained and controlled release "accurate" pharmaceuticals.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2023
期刊:中国全科医学
影响因子:--
作者:宋伟梅;王旭春;任浩;赵英;陈利民;仇丽霞
通讯作者:仇丽霞
DOI:10.1186/s12889-023-17011-w
发表时间:2023-11-06
期刊:BMC public health
影响因子:4.5
作者:
通讯作者:
DOI:--
发表时间:2021
期刊:中华疾病控制杂志
影响因子:--
作者:王旭春;翟梦梦;任浩;李美晨;全帝臣;张洁;陈利民;仇丽霞
通讯作者:仇丽霞
DOI:--
发表时间:2023
期刊:中国卫生统计
影响因子:--
作者:全帝臣;王华芳;李美晨;任浩;王旭春;翟梦梦;仇丽霞
通讯作者:仇丽霞
DOI:10.1038/s41598-022-11125-8
发表时间:2022-05-09
期刊:Scientific reports
影响因子:4.6
作者:
通讯作者:
基于遗传算法的多目标药物提取条件优化分析方法研究
  • 批准号:
    30872183
  • 项目类别:
    面上项目
  • 资助金额:
    28.0万元
  • 批准年份:
    2008
  • 负责人:
    仇丽霞
  • 依托单位:
国内基金
海外基金